Below are the financial statements of BridgeBio Pharma, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in millions of USD | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue, net | 221.9a | 9.3a | 77.65a |
| Operating costs and expenses | — | — | — |
| Cost of revenue | -3.88a | -2.45a | -3.43a |
| Research and development | -506.46a | -455.71a | -399.46a |
| Selling, general and administrative | -288.93a | -150.59a | -143.19a |
| Restructuring, impairment and related charges | -15.61a | -7.93a | -43.77a |
| Total operating costs and expenses | -814.88a | -616.67a | -589.85a |
| Loss from operations | -592.97a | -607.37a | -512.2a |
| Other income (expense), net | — | — | — |
| Interest income | 17.25a | 18.04a | 7.54a |
| Interest expense, net | -99.29a | -81.29a | -80.44a |
| Gain on deconsolidation of subsidiaries | 178.32a | 0a | 0a |
| Loss on extinguishment of debt | -26.59a | 0a | 0a |
| Net loss from equity method investments | -31.18a | 0a | 0a |
| Gain from sale of priority review voucher, net | 0a | 0a | 107.95a |
| Other income (expense), net | 12.27a | 17.37a | -7.5a |
| Total other income (expense), net | 50.78a | -45.88a | 27.55a |
| Loss before income taxes | -542.19a | -653.25a | -484.65a |
| Income tax expense | -1.15a | 0a | 0a |
| Net loss | -543.35a | -653.25a | -484.65a |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 7.59a | 10.05a | 3.47a |
| Net loss attributable to common stockholders of BridgeBio | -535.76a | -643.2a | -481.18a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore BridgeBio Pharma’s data sources below and access millions more through our Disclosure Search.